Coya Therapeutics (COYA) Net Income towards Common Stockholders (2023 - 2025)
Historic Net Income towards Common Stockholders for Coya Therapeutics (COYA) over the last 3 years, with Q3 2025 value amounting to -$2.4 million.
- Coya Therapeutics' Net Income towards Common Stockholders rose 4533.17% to -$2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.9 million, marking a year-over-year decrease of 8825.45%. This contributed to the annual value of -$14.9 million for FY2024, which is 8629.31% down from last year.
- Coya Therapeutics' Net Income towards Common Stockholders amounted to -$2.4 million in Q3 2025, which was up 4533.17% from -$6.1 million recorded in Q2 2025.
- Coya Therapeutics' 5-year Net Income towards Common Stockholders high stood at $1.8 million for Q4 2023, and its period low was -$7.3 million during Q1 2025.
- Its 3-year average for Net Income towards Common Stockholders is -$3.7 million, with a median of -$3.6 million in 2023.
- Per our database at Business Quant, Coya Therapeutics' Net Income towards Common Stockholders crashed by 32479.04% in 2024 and then soared by 4533.17% in 2025.
- Over the past 3 years, Coya Therapeutics' Net Income towards Common Stockholders (Quarter) stood at $1.8 million in 2023, then crashed by 324.79% to -$4.1 million in 2024, then surged by 40.37% to -$2.4 million in 2025.
- Its last three reported values are -$2.4 million in Q3 2025, -$6.1 million for Q2 2025, and -$7.3 million during Q1 2025.